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Primary eccrine adenocarcinoma of the skin is a rare 
adnexal neoplasm, with a limited number of reported 
cases in the literature (1). Gross features of the tumour 
are undefined, and variants have been reported; therefore, 
histological evaluation is necessary for diagnosis (1, 2). 
Exclusion of a visceral adenocarcinoma with cutaneous 
metastasis is another important criterion for confirming 
a diagnosis of primary eccrine adenocarcinoma (2, 3).
Traditionally, the recommended treatment for pri-
mary eccrine adenocarcinoma of the skin has been 
wide local excision with possible regional lymph node 
dissection (4); however, given the lack of published 
reports, there is no standard of care for management. 
Recently, Mohs micrographic surgery (MMS) has 
become an attractive treatment option for this type of 
tumour (3, 5, 6). For the past decade, we have treated 
primary eccrine adenocarcinomas of the skin based on 
a clinical assessment involving a total body computed 
tomographic and positron emission scan (positron 
emission tomography/computed tomography; PET/CT 
scan) for metastatic work-up and MMS for complete 
removal of the tumour. Because the role of lymph node 
dissection remains controversial (4), sentinel lymph 
node biopsy (SLNB) or regional lymph node dissection 
have been performed in selected cases.
CASE REPORTS
The Retrospective Clinical Data Retrieving System (Severance 
Hospital, Seoul, Korea) was used to obtain information from pa-
tients who were diagnosed with primary eccrine adenocarcinoma 
of the skin between January 2005 and November 2014. Five 
patients (4 males and 1 female; median age 51 years; age range 
29–70 years) were identified from our search. Detailed clinical 
patient characteristics are summarized in Table I. On histologi-
cal review, 2 patients were confirmed as having classic eccrine 
adenocarcinoma, and the remaining 3 patients were classified as 
having mucinous eccrine adenocarcinoma (Fig. S11) (5). Clinically, 
both types of eccrine adenocarcinoma of the skin presented with 
either deep or superficial nodular lesions. The tumour was confined 
to the head and neck area in 4 of the 5 patients, and one case of 
mucinous eccrine adenocarcinoma affected the finger web space. 
All 5 primary eccrine adenocarcinomas of the skin were treated 
by MMS, and various clinical features of the tumours are shown 
in Fig. S21. Two patients had lesions that were previously treated 
by either wide local excision (WLE) with adjuvant radiation (# 
1) or radiation alone (# 4) and visited our clinic after initial recur-
rence (time to recurrence was 50 and 53 months, respectively). 
These 2 patients underwent MMS for control of local recurrence. 
The remaining 3 patients had primary occurring lesions and were 
initially treated by MMS.
Extensive clinical examination and PET/CT scan revealed all 
5 cases to be a primary eccrine adenocarcinoma of the skin. One 
case initially showed the presence of tumour cells in regional 
lymph nodes. Specifically, Patient 2 showed a mild intensity of 
fluorodeoxyglucose (FDG) uptake in her right neck lymph node. 
Modified radical neck dissection (MRND) was performed for 
evaluation and treatment, and metastatic involvement in 1 of 19 
regional lymph nodes was confirmed. We considered SLNB in the 
other 4 patients with clinically and PET/CT negative node basins. 
Patient 5, who was diagnosed with mucinous eccrine adenocar-
cinoma on his finger web space, was treated by MMS along with 
axillary SLNB. Consistent with a negative metastatic work-up 
result by PET/CT scan, this patient presented with a negative 
SLNB specimen. Based on the unpredictable lymphatic drainage 
patterns of the head and neck area and the potential morbidity of 
neck dissection, the remaining 3 patients with lesions affecting 
the face were put on a biannual follow-up programme without 
SLNB or MRND.
Because all 5 lesions affected either the face or the finger web 
space, skin preservation was required. In a previous study, Wil-
demore et al. (7) reported that single-stage MMS with 4–5-mm 
margins was able to clear malignant eccrine neoplasms in all cases, 
suggesting that narrower margins also seem appropriate for areas, 
such as the face, that require maximum tissue saving. Therefore, 
we employed 3-mm margins for the first layer of MMS with 
frozen section control. Only one case of mucinous eccrine adeno-
carcinoma involving the lateral canthal area required 2 layers of 
MMS, whereas the other 4 were cleared by 1-stage MMS. Patient 
2 underwent additional MRND, but no patients needed adjuvant 
radiation and/or chemotherapy. The mean period of follow-up after 
MMS was 73.0 ± 32.5 months, and only one patient presented with 
local recurrence during this follow-up period (# 4). This patient 
had undergone MMS after an initial recurrence. A second MMS 
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years Site Pathological diagnosis Prior therapy Treatment
Follow-up, 
months Recurrence
1 M/70 Temple Classic eccrine adenocarcinoma WLE with adjuvant RTx MMS 120 Before MMS
2 F/29 Nasolabial fold Classic eccrine adenocarcinoma None MMS with MRND 90 None
3 M/51 Lateral canthus Mucinous eccrine adenocarcinoma None MMS 60 None
4 M/53 Cheek Mucinous eccrine adenocarcinoma RTx MMS 59 Yes
5 M/49 4th finger web space Mucinous eccrine adenocarcinoma None MMS with SLNB 36 None
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was performed, and this patient has been checked every 6 months 
for 3 years without further recurrence or metastasis.
DISCUSSION
Primary eccrine adenocarcinoma of the skin is a rare 
tumour that originates in the sweat gland (1, 8). There 
are only about 150 cases of primary mucinous eccrine 
adenocarcinoma of the skin documented in the literature, 
and primary classic eccrine adenocarcinomas of the 
skin are also rarely reported (5, 9, 10). Lesions present 
as painless papular or nodular masses, ranging from 5 
to 120 mm, with a predilection for the head and neck 
area (1, 2). Primary mucinous eccrine adenocarcinoma 
of the skin has low metastatic potential, but frequently 
shows local recurrence following excision (5, 6). With 
respect to primary classic eccrine adenocarcinoma of 
the skin, a high incidence of regional lymph node and 
visceral metastases has been reported (42% and 38%, 
respectively) (11); however, recently, Avraham et al. (9) 
reported relatively lower rates of metastasis for classic 
eccrine adenocarcinoma, with an overall 5-year survival 
rate of 81%. In the present study, one case of classic ec-
crine adenocarcinoma initially showed metastatic spread 
to a regional lymph node, but was successfully treated 
with MRND.
Exclusion of skin metastasis from another site is an 
important criterion for diagnosing and managing primary 
eccrine adenocarcinoma of the skin. However, given the 
rarity of this disease, there is little information available 
on the role of imaging techniques for these tumours (12, 
13). While carcinoma of other organs, such as breast or 
gastrointestinal tract, was not detected in our patients 
during the follow-up period, the usefulness of supportive 
PET/CT scan for evaluating metastatic adenocarcinoma 
and establishing the diagnosis remains unclear from this 
small cases series. Moreover, although the histopatholo-
gical results following MRND in Patient 2 and the SLNB 
in Patient 5 correlated with the PET/CT results, we are 
unable to comment on whether PET/CT is an effective 
technique for the nodal evaluation of this tumour. Due 
to the fact that a prospective large-scale longitudinal 
study to address these issues may be difficult for this 
rare tumour, we believe that PET/CT may provide benefit 
for the management of primary eccrine adenocarcinoma 
of the skin.
All 5 patients evaluated in this study are currently 
alive, with no evidence of metastasis after treatment with 
MMS. While local recurrence after MMS was observed 
in one case of recurrent mucinous eccrine adenocarci-
noma, there was no recurrence in patients initially treated 
with MMS. Kamalpour et al. (10) performed a systematic 
review and meta-analysis of outcomes after surgical 
treatment of primary mucinous eccrine adenocarcinoma 
of the skin and found a total of 15 cases in the literature 
that were treated by MMS. Among these 15 patients, 
recurrence was observed in only 2 (13%), and there were 
no cases of metastasis. Adefusika et al. (5) reviewed 10 
cases of sweat gland carcinomas surgically treated at 
the Mayo Clinic and found no episodes of recurrence or 
metastases after treatment with MMS. Considering the 
potential for aggressive behaviour following metastasis 
and difficult anatomical locations, such as the face and 
hand, MMS can be suggested as an ideal treatment op-
tion for this rare sweat gland neoplasm. Collectively, the 
data suggest that MMS leads to complete removal of the 
tumour with minimal chance for future recurrence and 
maximum conservation of surrounding tissue.
In conclusion, our data suggest that MMS may be an 
effective therapeutic option for primary eccrine adeno-
carcinoma of the skin, particularly in primary occurring 
cases. Although follow-up of 4 patients with clinically 
and radiologically negative node basins did not result 
in regional or distant metastasis, further study with a 
larger number of patients is needed to confirm whether 
in-depth investigation of the lymph nodes is necessary 
in this population.
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